期刊文献+

Proliferative response of human prostate cancer cell to hormone inhibited by androgen receptor antisense RNA

Proliferative response of human prostate cancer cell to hormone inhibited by androgen receptor antisense RNA
原文传递
导出
摘要 Background The failure of endocrine treatment for advanced prostate cancer might be related to aberrant activation of androgen receptor (AR) Prostate cancer cell line LNCaP contains AR that can be activated by androgen, estrogen and progesterone This study was set to investigate the effects of antisense AR RNA on growth of LNCaP cultured in medium containing varied concentrations of R1881, 17β-estradiol, and progesterone, respectively Methods LNCaP cells transfected with antisense AR RNA retroviral vector pL-AR-SN were designated as LNCaP as-AR . LNCaP cells containing empty vector pLXSN served as LNCaP Neo . LNCaP and LNCaP Neo were taken as controls In vitro cell growth assay, proliferative cells of LNCaP and tranfected LNCaPs were counted by typan staining when they cultured with synthetic androgen R1881, 17β-estradiol, and progesterone, respectively Results Growth of LNCaP as-AR was inhibited significantly ( P <0 05) compared with that of LNCaP and LNCaP Neo at 1 nmol/L R1881, 10 nmol/L 17β-estradiol, and 1 nmol/L progesterone, respectively No difference was seen between LNCaP and LNCaP Neo ( P >0 05) Microscopic observation showed that LNCaP and LNCaP Neo cells grew well, but only few LNCaP as-AR cells were alive Conclusions Our observations indicate that antisense AR RNA retroviral vector pL-AR-SN could change androgen-independent characteristics of LNCaP cells, which might shed some novel insights into the treatment of androgen-independent prostate cancer Background The failure of endocrine treatment for advanced prostate cancer might be related to aberrant activation of androgen receptor (AR) Prostate cancer cell line LNCaP contains AR that can be activated by androgen, estrogen and progesterone This study was set to investigate the effects of antisense AR RNA on growth of LNCaP cultured in medium containing varied concentrations of R1881, 17β-estradiol, and progesterone, respectively Methods LNCaP cells transfected with antisense AR RNA retroviral vector pL-AR-SN were designated as LNCaP as-AR . LNCaP cells containing empty vector pLXSN served as LNCaP Neo . LNCaP and LNCaP Neo were taken as controls In vitro cell growth assay, proliferative cells of LNCaP and tranfected LNCaPs were counted by typan staining when they cultured with synthetic androgen R1881, 17β-estradiol, and progesterone, respectively Results Growth of LNCaP as-AR was inhibited significantly ( P <0 05) compared with that of LNCaP and LNCaP Neo at 1 nmol/L R1881, 10 nmol/L 17β-estradiol, and 1 nmol/L progesterone, respectively No difference was seen between LNCaP and LNCaP Neo ( P >0 05) Microscopic observation showed that LNCaP and LNCaP Neo cells grew well, but only few LNCaP as-AR cells were alive Conclusions Our observations indicate that antisense AR RNA retroviral vector pL-AR-SN could change androgen-independent characteristics of LNCaP cells, which might shed some novel insights into the treatment of androgen-independent prostate cancer
机构地区 Department of Urology
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2004年第5期684-688,共5页 中华医学杂志(英文版)
基金 ThisworkwassupportedbyagrantfromtheNationalNaturalScienceFoundationofChina (No 3 9770 740 )
关键词 androgen receptor antisense RNA prostatic neoplasms androgen receptor · antisense RNA · prostatic neoplasms
  • 相关文献

参考文献12

  • 1C. J. Tyrrell,G. M. Blake,P. Iversen,A. V. Kaisary,I. Melezinek.The non-steroidal antiandrogen, bicalutamide (’Casodex’), may preserve bone mineral density as compared with castration: results of a preliminary study[J].World Journal of Urology.2003(1)
  • 2Martin Gleave,Hideake Miyake,Uwe Zangemeister-Wittke,Burkhard Jansen.Antisense Therapy: Current Status in Prostate Cancer and Other Malignancies[J].Cancer and Metastasis Reviews.2002(1)
  • 3BalkSP.Androgenreceptorasatargetinandrogen independentprostatecancer[].Urology.2002
  • 4CuligZ,KlockerH,BartschG ,etal.Androgenreceptorsinprostatecancer[].EndocrRelatCancer.2002
  • 5CuligZ,KlockerH,BartschG ,etal.Androgenreceptormutationsincarcinomaoftheprostate:significanceforendocrinetherapy[].AmJPharmacogenomics.2001
  • 6RiniBI,SmallEJ.Prostatecancerupdate[].CurrOpinOncol.2002
  • 7TyrrellCJ,BlakeGM,IversenP ,etal.Thenon steroidalantiandrogen,bicalutamide("Casodex"),maypreservebonemineraldensityascomparedwithcastration:resultsofapreliminarystudy[].WorldJUrol.2003
  • 8TaplinME,RajeshkumarB,HalabiS ,etal.Androgenreceptormutationsinandrogen independentprostatecancer:CancerandLeukemiaGroupBStudy9663[].JClinOncol.2003
  • 9CuligZ,HobischA,CronauerMV ,etal.Mutantandrogenreceptordetectedinanadvanced stageprostatecarcinomaisactivatedbyadrenalandrogensandprogesterone[].Molecular Endocrinology.1993
  • 10SusukiH,AkakuraK,KomiyaA ,etal.Codon877mutationintheandrogenreceptorgeneinadvancedprostatecancer:relationtoantiandrogenwithdrawalsyndrome[].Prostate.1996

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部